21179-04-4Relevant articles and documents
α-Fluorination of Sulfides with N-Fluoropyridinium Triflates
Umemoto, Teruo,Tomizawa, Ginjiro
, p. 3625 - 3630 (1986)
The reaction of sulfides possessing α-hydrogen with various N-fuoropyridinium salts was examined.While the fluorinating power increased in the order of N-fluoro-2,4,6-trimethylpyridinium triflate 12, and 3 no longer produced the α-fluoro sulfide.Triflate 1 was more reactive than the corresponding tetrafluoroborate 4.Thus, it was shown that 1 satisfactorily fluorinated various kinds of sulfides under very mild conditions, giving α-fluoro sulfides.A two-step mechanism, oxidative fluorination of sulfur and Pummerer-type rearrangement, was proposed for the fluorination.The corresponding α-fluoro sulfoxide or sulfones were easily prepared from the sulfides by successive fluorination-oxidation procedure.
-
Olah,G.A.,Ohyama,T.
, p. 319 - 320 (1976)
-
1,2-azaborine cations
Marwitz, Adam J. V.,Jenkins, Jesse T.,Zakharov, Lev N.,Liu, Shih-Yuan
, p. 7444 - 7447 (2010)
Positively brilliant: The first examples of 1,2-azaborine cations have been prepared and their structure and optoelectronic properties characterized (see picture). 1,2-Azaborine cations exhibit solid-state fluorescence that is distinct from their neutral all-carbon analogues, and the 1,2-azaborine moiety is a critical component for the optoelectronic properties. There is a potential for the utility of these complexes in materials applications.
Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
-
, (2008/06/13)
The subject matter of the present invention is a cyclic or linear tetra- or pentapeptide binding to somatostatin receptors. The compounds of the invention are characterised in that they contain the radical of an amino carboxylic acid bearing a five-membered ring in the peptide backbone which may optionally contain O, S, Se, N, or P. These compounds are easy to prepare and display increased stability against peptidases. The compounds of the present invention induce apoptosis of tumour cells and the use of said compounds for cancer therapy is described. In particular, the compounds are characterised in that they are active even against tumour cells displaying resistance against other somatostatin derivatives such as octreotide. In addition, the use of the compounds of the invention for tumour diagnosis by means of positron-emission tomography is described, as well as their use as agents against neurogenic inflammation.